Biogen/Elan file Tysabri at FDA and EMA for first line treatment of Multiple Sclerosis

Biogen Idec and Elan Corporation have announced that they have submitted applications to the FDA and European Medicines Agency requesting updates to the Tysabri (natalizumab) labels for treatment of Multiple Sclerosis. The applications request an expanded indication that would include first-line use for people living with certain relapsing forms of Multiple Sclerosis who have tested negative for antibodies to the JC virus (JCV). A formal assessment of both applications is ongoing.